AI Offers New Pathways to Strengthen Site Leadership in Underserved Regions
Artificial intelligence can help identify key opinion leaders in emerging markets, improving site influence, patient engagement, and trial success.
Gen Li, PhD, MBA, president of Phesi, discussed the company's analysis on global inequity in breast cancer development in a recent video interview with Applied Clinical Trials.
- Geographic concentration of breast cancer trial leaders is in the US and China.
- Operational barriers in lower-income countries are due to traditional business models.
- Artificial intelligence (AI) and machine learning can implement a patient-centric approach.
Li emphasized the importance of identifying local leaders and redistributing trial workloads to improve recruitment.
AI can identify and activate new sites, addressing the lack of local KOLs in underserved areas.
Author's summary: AI helps identify key opinion leaders in emerging markets.
More News
- Major Candy Company Files Chapter 11 Bankruptcy Amid Halloween Week Shock - CCE l ONLINE NEWS
- Closed-Loop Insulin System Improves Glucose Control in Pregnant Women with Type 1 Diabetes: JAMA
- Accessible, low-cost biomedical innovations at Tufts’ research lab - The Tufts Daily
- US Weekly Headlines: Policy change for Pentagon officials, government shutdown continues
- Benz Hui Dies At 76 from Cancer-Related Organ Failure
- Australian government bans Dutch volleyball rapist
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Mark Rutte’s Dutch liberals were dominant for years. Now the party is bleeding support.
- Utica outlasts Warren Cousino; Lakeview topples rival Lake Shore; Chippewa Valley, Warren Mott also record lopsided wins